

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A method for identifying inhibitors of protein kinases comprising:

~~covalently attaching identifying at least one first module having one or more functional groups each capable of covalently or non-covalently binding to catalytic residues of the protein kinase, wherein said identifying comprises covalently attaching the at least one first module to a peptide scaffold which comprises a peptide substrate for a protein kinase and identifying one or more functional groups on the first module which preferentially bind each of which is capable of covalently or non-covalently binding to catalytic residues of the protein kinase;~~

~~producing one or more combinations of covalently attaching the at least one first module covalently attached to at least one second module which comprises provides a non-peptide scaffold, wherein the at least one second module comprises an indole, to form one or more combinations of the first and second modules, and wherein said covalently attaching comprises substituting the at least one second module is substituted for the peptide scaffold and is capable of occupying the same binding region of the protein kinase as the peptide scaffold;~~

screening the one or more combinations of the first and second modules for protein kinase inhibition; and

selecting combinations of the first and second modules which inhibit protein kinase activity.

2. (canceled)

3. (previously presented) The method according to claim 1, wherein the at least one first module comprises a functional group selected from the group consisting of boronic acid, a hydroxyl group, phosphonic acid, sulfamic acid, a guanidino group, carboxylic acid, an aldehyde, an amide, and hydroxymethylphosphonic acid.

4. (previously presented) The method according to claim 3, wherein the at least one first module comprises two or more functional groups.

5. (previously presented) The method according to claim 3, wherein the at least one first module comprises a boronic acid group.

6. (previously presented) The method according to claim 3, wherein the at least one first module comprises a hydroxyl group.

7. (previously presented) The method according to claim 3, wherein the at least one first module comprises an amide group.

8. (original) The method according to claim 7, wherein the amide group is a vicinal tricarbonyl amide.

Claims 9-12 (canceled)

13. (previously presented) The method according to claim 1, wherein the at least one first module further comprises a linear chain comprising between one and three carbon atoms which links the at least one first module to the at least one second module.

14. (original) The method according to claim 13, wherein one of the carbon atoms in the linear chain is substituted with a nitrogen, oxygen or sulfur atom.

15. (original) The method according to claim 1, wherein the protein kinase is a protein tyrosine kinase.

16. (original) The method according to claim 15, wherein the protein tyrosine kinase is selected from the group consisting of pp60^{c-src}, p56^{lck}, ZAP kinase, platelet derived growth factor receptor tyrosine kinase, Bcr-Abl, VEGF receptor tyrosine kinase, and epidermal growth factor receptor tyrosine kinase, and epidermal growth factor receptor-like tyrosine kinases.

17. (original) The method according to claim 16, wherein the protein tyrosine kinase is pp60^{c-src}.

18. (original) The method according to claim 1, wherein the protein kinase is a protein serine kinase.

19. (previously presented) The method according to claim 18, wherein the protein serine kinase is selected from the group consisting of MAP kinase, protein kinase C, and CDK kinase.

20. (previously presented) The method according to claim 1, further comprising:

covalently attaching one or more specificity side chain elements to the one or more combinations of the first and second modules.

21. (canceled)

22. (original) The method according to claim 1, wherein the protein kinase inhibitor inhibits protein kinase activity but does not inhibit ATP binding to the protein kinase

Claims 23-69 (canceled)